bTAE-HAIC

PROCEDURE2 trials

Sponsors

Sun Yat-sen University

Conditions

CamrelizumabHepatocellular CarcinomaImmunotherapyLenvatinibLiver DiseasesSintilimab

Unknown Phase

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

RecruitingNCT06061276

Sun Yat-sen UniversityCamrelizumab, Hepatocellular Carcinoma, Immunotherapy +2

Start: 2024-05-20End: 2025-12-30Target: 40Updated: 2024-09-23

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

RecruitingNCT06070636

Sun Yat-sen UniversityHepatocellular Carcinoma, Immunotherapy, Lenvatinib +2

Start: 2024-05-20End: 2025-06-30Target: 30Updated: 2024-08-09

Related Papers

Sequential bTAE-HAIC combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma: A single-center perspective.

Journal of Clinical Oncology2026-05-27

A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial.

Journal of Clinical Oncology2026-05-27